Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV vs Subcutaneous Neostigmine for ACPO
NCT04951726Phase 4Unknown
- Sponsor
- University of Southern California
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of neostigmine in acute colonic pseudo-obstruction (ACPO) (2 arms), sponsored by University of Southern California. Primary endpoint: Radiographic resolution of colonic pseudo obstruction at 24 hours. Status: unknown.
02
Drugs
neostigmine
03
Conditions
acute colonic pseudo-obstruction (ACPO)
Beyond the preview
Go deeper on NCT04951726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951726.